Duovir N Tablets

Q1: What is Duovir N used for?

Duovir N is a fixed-dose combination of Lamivudine 150mg + Zidovudine 300mg + Nevirapine 200mg. It provides a complete triple HIV therapy (dual NRTI + NNRTI) in a single tablet. It is widely used in resource-limited settings for its cost-effectiveness and established efficacy.

Q2: How do the three components work together?

Lamivudine and Zidovudine (both NRTIs) inhibit HIV reverse transcriptase as chain terminators — blocking viral RNA from being copied to DNA. Nevirapine (NNRTI) binds directly to reverse transcriptase at a different site, providing synergistic inhibition with a higher barrier to resistance than either NRTI class alone.

Q3: What is the Nevirapine 'lead-in' period and why is it essential?

Nevirapine MUST be started at 200mg once daily for 14 days before increasing to 200mg twice daily. This lead-in period allows hepatic enzyme induction, reducing rash and hepatotoxicity risk from ~30% to approximately 5%. Skipping the lead-in dramatically increases toxicity risk.

Q4: Who should NOT start Nevirapine-based regimens?

Women with CD4 counts above 250 cells/mm³ and men with CD4 above 400 cells/mm³ have significantly higher risk of Nevirapine-induced hepatotoxicity. Alternative regimens should be used in these patients. This is a WHO and national guideline recommendation.

Q5: What are the most common side effects?

Rash (common, especially in first 6 weeks), nausea, headache, fatigue, and diarrhea. Zidovudine can cause anemia and neutropenia. Nevirapine can cause hepatotoxicity.

Q6: What serious side effects require emergency care?

Seek immediate care for: any rash that spreads or blisters (possible Stevens-Johnson syndrome from Nevirapine), signs of severe liver damage (jaundice, severe abdominal pain, dark urine), or severe anemia symptoms (extreme fatigue, pallor, shortness of breath from Zidovudine).

Q7: What is Stevens-Johnson syndrome in the context of Nevirapine?

SJS is a rare but potentially fatal skin reaction causing widespread blistering of skin and mucous membranes. It requires immediate hospital care. Any rash appearing after 2 weeks on Nevirapine — particularly a rash that blisters or involves the mouth/eyes — requires emergency evaluation.

Q8: How does Zidovudine cause anemia?

Zidovudine inhibits mitochondrial DNA synthesis in bone marrow cells, reducing red blood cell production. Regular CBC monitoring is essential — hemoglobin and neutrophil count should be checked at baseline and every 3 months. Severe anemia may require switching to an alternative NRTI.

Q9: Can Duovir N be used during pregnancy?

Lamivudine is safe in pregnancy. Nevirapine and Zidovudine are used in pregnancy, but Nevirapine's CD4-dependent hepatotoxicity risk must be considered. Many HIV programs now prefer TDF/FTC + Dolutegravir in pregnancy. Discuss with your HIV/obstetric specialist.

Q10: What monitoring is required during Duovir N therapy?

Full blood count (CBC) every 3 months (Zidovudine anemia/neutropenia risk). Liver function tests at baseline, at 2 weeks, at 4 weeks, and then monthly for first 3 months (Nevirapine hepatotoxicity). CD4 and viral load every 3–6 months.

Q11: How should Duovir N be stored?

Store at room temperature away from light and moisture. Keep in original packaging out of reach of children.

Q12: Do I need a prescription for Duovir N?

Yes. Duovir N requires specialist HIV prescribing with CD4 count assessment before initiating (to exclude high-CD4 Nevirapine contraindication) and regular liver function and blood count monitoring.